Diroximel fumarate

Diroximel fumarate
Clinical data
Trade names	Vumerity
Other names	ALKS-8700
AHFS/Drugs.com	Monograph
MedlinePlus	a620002
License data	US DailyMed: Diroximel fumarate;
Pregnancy; category	AU: B3; ;
Routes of; administration	By mouth
ATC code	L04AX09 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Protein binding	Monomethyl fumarate (MMF): 27–45%
Metabolism	Esterases, citric acid cycle
Metabolites	MMF (active), hydroxyethyl succinimide (HES, inactive), CO2 (inactive)
Elimination half-life	1 hour
Excretion	MMF: 60% lung, 15.5% urine (?), 0.9% faeces; HES: 58–63% urine
Identifiers
	IUPAC name methyl 2-(2,5-dioxopyrrolidin-1-yl)ethyl (2E)-but-2-enedioate;
CAS Number	1577222-14-0;
PubChem CID	73330464;
DrugBank	DB14783;
ChemSpider	57423290;
UNII	K0N0Z40J3W;
KEGG	D11154;
ChEMBL	ChEMBL3989944;
CompTox Dashboard (EPA)	DTXSID101026181 ;
Chemical and physical data
Formula	C11H13NO6
Molar mass	255.226 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC(=O)C=CC(=O)OCCN1C(=O)CCC1=O;
	InChI InChI=1S/C11H13NO6/c1-17-10(15)4-5-11(16)18-7-6-12-8(13)2-3-9(12)14/h4-5H,2-3,6-7H2,1H3/b5-4+; Key:YIMYDTCOUQIDMT-SNAWJCMRSA-N;

Diroximel fumarate, sold under the brand name Vumerity, is a medication used for the treatment of relapsing forms of multiple sclerosis (MS). It acts as an immunosuppressant and anti-inflammatory drug. Its most common adverse effects are flushing and gastrointestinal problems.

Diroximel fumarate was approved for medical use in the United States in October 2019, and in the European Union in November 2021.